A biotech company’s Alzheimer’s drug didn’t meet expectations — and the stock is plunging

Short resume:

alzheimer
70%
neurotrope
70%
reuters
60%
company
60%

May 1 (Reuters) – Neurotrope Inc said on Monday the smaller dose of its experimental Alzheimer’s drug met the main goal in a small mid-stage study, but shares tumbled 36 percent in premarket trading as investors were not impressed with the data.
Source Business Insider
Read More…

More News

Be the first to comment

Leave a Reply

Your email address will not be published.


*